Clinical trial
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT03329950
Study timeline
Study start (actual)2017-12-01Date precision: day
Registry last updated2024-03-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Melanomaunresolved
Non-small Cell Lung Cancerunresolved
Breast Cancerunresolved
Gastric Cancerunresolved
Renal Cell Carcinomaunresolved
Ovarian Cancerunresolved
Cholangiocarcinomaunresolved
Bladder Urothelial Carcinomaunresolved
Pancreatic Adenocarcinomaunresolved
Colorectal Cancerunresolved
Esophageal Cancerunresolved
Hepatic Cancerunresolved
Head and Neck Cancerunresolved
Primary Peritoneal Cancerunresolved
Fallopian Tube Cancerunresolved
Other Solid Tumorsunresolved
Diffuse Large B-cell Lymphoma (DLBCL)unresolved
Mantle Cell Lymphomaunresolved
Indolent B-cell Lymphomasunresolved
Non-Hodgkin Lymphomaunresolved
Follicular Lymphomaunresolved
Lymphoplasmacytic Lymphomaunresolved
Waldenstrom's Diseaseunresolved
Marginal Zone Lymphomaunresolved
Mucosa Associated Lymphoid Tissueunresolved
Small Lymphocytic Leukemiaunresolved
Interventions
Sponsors & collaborators
Celldex Therapeuticslead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
New YorkNew York, United States2HoustonTexas, United States1PhiladelphiaPennsylvania, United States1AtlantaGeorgia, United States1PortlandOregon, United States1OmahaNebraska, United States1ProvidenceRhode Island, United States1ScottsdaleArizona, United States1AugustaGeorgia, United States1CantonOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03329950 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.